Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Corni Fructus extract may help manage benign prostatic hyperplasia by reducing prostate cell growth and inflammation.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This review highlights that several clinical and epidemiological studies link a diet high in terpenoid compounds with a decreased risk of prostate cancer, supporting the potential use of terpenoids as therapeutic ingredients in treating this disease.

This laboratory study found that PI extract, along with its metabolites Ang and Mac, inhibited cell proliferation and protein expression linked to pathways involved in BPH, suggesting potential for therapeutic use, although the Ang-Mac combination showed no significant effect on apoptosis through the p53 pathway.

In this study, low-dose BPA was associated with induced prostatic hyperplasia in rats, potentially mediated by COX-2 and L-PGDS through pathways involving cell proliferation and apoptosis.

This review discusses the potential role of FGF5 as a therapeutic target in prostate cancer and other conditions but reports no new results, highlighting a need for further research on FGF5 inhibitors.

This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study observed that low-dose intrauterine exposure to finasteride alters postnatal prostate development in male and female Mongolian gerbils, showing sex-specific differences in receptor expression and tissue changes.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

This review discusses the structure, expression, regulation, and potential roles of NcoA4 in cancer and other pathologies, reporting no new experimental findings.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

This study demonstrated that an ethanol extract of Connarus semidecandrus Jack showed potential anti-androgenic alopecia effects in a testosterone-induced model, suggesting a possible treatment option for hair loss.

In this case study, a 3-year-old German Shepherd treated for an enlarged prostate with medication and surgery showed a significant prostate size reduction by 93.9% over 138 days, ruling out neoplastic processes.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This article discusses the hypothesis that mechanisms driving androgenic alopecia may reduce the risk and proliferation of prostate cancer by increasing prostaglandin D2 levels but presents no new clinical findings.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This study found that Ganoderma lucidum extracts showed weak 5alpha-reductase inhibition but significantly inhibited prostate cell proliferation and testosterone-driven prostate growth in rats, suggesting potential as an ingredient for treating androgen-induced diseases.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

In this study, finasteride exposure in human prostatic cell lines did not affect cell proliferation but significantly reduced MMP activity and increased TIMP expression, potentially inhibiting tumor cell invasion and metastasis.

In this study, Paljeong-san pharmacopuncture reduced dihydrotestosterone levels and inhibited prostate tissue proliferation in a rat model of benign prostatic hyperplasia.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study observed that intrauterine and early postnatal exposure to finasteride affected prostatic development in Mongolian gerbils, with significant sex-based differences, particularly higher alterations in female prostates.

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

This study found that cell strains overexpressing the androgen receptor proliferated better in low or no DHT conditions and translocated AR more efficiently than control strains.

This study found that new curcumin analogues, such as ASC-J9, can inhibit prostate cancer cell growth by promoting androgen receptor degradation.

This review explores the potential impact of hormonal changes during aging on benign prostate hyperplasia-related urinary symptoms and metabolic syndrome, highlighting the hypothesis of a male PCOS-equivalent but reports no new clinical results.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.